Biohaven CEO Vlad Coric (Photo Credit: Andrew Venditti)

January 18, 2021 11:48 AM ESTUpdated January 19, 07:20 AM

Pssst: That big Biohaven Alzheimer's study? It was a bust. Even the subgroup analysis execs touted was a flop

You know it’s bad when a biopharma player plucks out a subgroup analysis for a positive take — even though it was way off the statistical …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE LOG IN

ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Lilly shuffles key executive positions; Mikael Dolsten takes another post-Pfizer assignment

Revolution’s KRAS drugs appear competitive in several lung cancer settings

AstraZeneca reports Phase 3 win for Imfinzi; Roche to build new manufacturing site in China

Corvus' early-phase atopic dermatitis data prompt stock rally

Iovance stock plummets after lowered full-year guidance, missed analyst expectations for Amtagvi

sponsored

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges